Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (NCT01999868), a randomized phase 2 study. The primary outcome is Percentage of Participants Who Experienced Psoriasis Relapse (Treating Drop-Outs as Relapse).

2. Clinical Question

3. Trial Design

This is a completed Phase 2, randomized, quadruple-masked, parallel-group trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The registry lists an enrollment of 108. The study start date is 2014-03-19, and the primary completion date is 2017-12-07. These record details describe the trial structure and administrative timeline; they do not establish what the treatment comparison found.

The design has a lead-in followed by random assignment. Participants received open-label ustekinumab at Weeks 0 and 4 during the lead-in. The primary analysis population consists of participants who were found eligible after the 12-week lead-in and underwent random assignment. This means the primary question concerns relapse after that common initial treatment period, rather than a comparison of the lead-in treatment against another treatment.

The randomized arm labels distinguish ustekinumab with abatacept or abatacept placebo from ustekinumab with ustekinumab placebo or abatacept placebo, as described in the record. The arm descriptions are incomplete, so further post-randomization treatment details are not reported in the registry record. The record identifies quadruple masking but does not specify which groups of people were masked or describe how masking was maintained.

The registry lists psoriasis as the condition and describes the purpose as determining whether ustekinumab followed by abatacept would prevent relapse in people with moderate to severe plaque psoriasis. It also lists secondary outcomes covering relapse under alternative drop-out assumptions, time to relapse, physician global assessment, dermatology-related quality of life, and adverse events. The randomized allocation, parallel structure, and masked treatment assignment are design features; they are not evidence of the size or precision of any treatment effect.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Enrolled participants received open-label ustekinumab in the lead-in phase (Week 0 to 12). Participants with at least 75% reduction in Psoriasis Area Severity Index (PASI) score at Week 12 compared to Week 0 were eligible for the blinded treatment phase (Week 12 to 40).

Lead-in Phase (Week 0 - 12)

Reasons for not completing this period:

Blinded Treatment Phase (Week 12 - 40)

Reasons for not completing this period:

Blinded Observation Phase (Week 40 - 88)

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The intent-to-treat population includes all participants who were found to be eligible after the 12-week lead-in period and underwent random assignment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Subjects that signed informed consent, were eligible for the study, and were administered at least one dose of open-label ustekinumab in the lead-in phase.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants Who Experienced Psoriasis Relapse (Treating Drop-Outs as Relapse), measured over Post-randomization (Week 12 to 88).

The primary endpoint is the percentage of participants who experienced psoriasis relapse during the interval from Week 12 to 88. The registry defines relapse as losing at least half of the initial improvement in the Psoriasis Area and Severity Index (PASI), assessed at Week 12. It also specifies that participants who terminated early are counted as having relapsed at the time of drop-out. This rule makes drop-out status part of the endpoint definition rather than leaving those participants out of the primary outcome by default.

PASI assesses psoriasis severity across the head and neck, upper extremities, trunk, and lower extremities. Redness, thickness, and scaling are assessed in each body area, with scores weighted by affected body surface area. The resulting score ranges from 0, no psoriasis present, to 72, very severe psoriasis. The endpoint uses change relative to Week 12 because the trial is asking whether relapse occurs after the lead-in response, not simply whether participants have psoriasis at any point.

A percentage is a binary-outcome summary: each participant is classified according to whether relapse occurred under the stated rule. This can make the clinical interpretation direct, but the meaning depends on the relapse definition and the treatment of drop-outs. The registry record does not report the observed percentages by arm or the primary comparison estimate, so the magnitude and precision of the result cannot be described from this record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods help distinguish the question a trial asks from the evidence it reports. In this trial, the primary question concerns the percentage of participants with a defined relapse after the lead-in. The registry describes random assignment and masking, but it does not report the primary arm-specific percentages, comparison estimate, confidence interval, or test result. The methods below explain general statistical concepts relevant to this kind of outcome; they do not reconstruct an unreported analysis.

What does a percentage endpoint represent?

A binary endpoint classifies each participant into an event category or a non-event category. The registry’s primary endpoint classifies relapse during the stated interval and counts early drop-outs as relapses. An arm-specific percentage would summarize the share of participants in that arm classified as having the event. A comparison can then be expressed using an absolute contrast, a relative contrast, or a statistical test. These summaries answer related but different questions: the absolute contrast concerns the separation in event frequency, while a relative contrast concerns how the frequencies compare proportionally.

Neither kind of summary can be recovered without the relevant observed outcome data. The record gives the primary endpoint definition but not the arm-specific outcomes or primary comparison. It would therefore be inappropriate to infer a treatment effect from enrollment, arm labels, or the existence of a randomized design.

What does randomization contribute?

Random assignment is intended to make treatment groups comparable in expectation with respect to factors that could affect the outcome. It supports a causal comparison when the allocation process is properly implemented and the analysis is appropriate to the trial question. It does not ensure that groups are exactly alike in every observed or unobserved feature, especially in a particular trial. The registry identifies the study as randomized but does not report the allocation procedure, concealment details, or baseline comparisons. Those details are not reported in the registry record.

The primary population is defined after the 12-week lead-in: eligible participants who underwent random assignment. This defines the target group for the stated primary outcome. It is not the same as an analysis of everyone initially enrolled unless all enrolled participants met the post-lead-in eligibility and randomization conditions; the record does not state that. The number enrolled is 108, but the record does not give a primary outcome denominator by arm in the registry record for this description.

How should precision be understood?

A confidence interval is a statistical range that communicates uncertainty around an estimated effect under the model and assumptions used. A narrow interval indicates greater precision than a wide interval, while the interval’s location helps show which effect values are compatible with the data. A confidence interval is not a guarantee that the true effect lies within the particular reported interval. No primary confidence interval is reported in the registry record, so the precision of the relapse comparison cannot be assessed.

A p-value, when reported, describes how unusual data at least as inconsistent with a specified null hypothesis would be under that hypothesis and the analysis assumptions. It does not measure the probability that the null hypothesis is true, and it does not quantify clinical importance. The registry record does not report a primary p-value. Even if a p-value were available, it would need to be considered alongside the estimated effect, its precision, the endpoint definition, and the analysis population.

Why do drop-out rules matter?

Drop-out can leave an outcome unobserved or require a defined assumption about what happened after withdrawal. The primary endpoint assigns relapse at drop-out. The registry also lists secondary analyses treating drop-outs as no relapse, treating relapse status as missing, treating drop-outs as relapse in time-to-event analysis, and censoring them in time-to-event analysis. These choices represent different assumptions about outcomes after withdrawal. None is automatically correct in every setting; their credibility depends on the reasons for drop-out, timing, follow-up, and the relationship between missingness and relapse.

In general, sensitivity analyses examine whether conclusions change under alternative reasonable assumptions. The presence of differently defined secondary outcomes indicates that the record lists alternative approaches to drop-outs, but results for those analyses are not reported in the registry record. Without those results or details of the underlying missingness, robustness cannot be judged.

What is the role of the planning illustration?

The record describes planning illustrations based on a fraction of the observed effect, a two-sided significance level of 0.05, equal allocation, and a normal approximation. It specifies that such calculations are illustrations rather than the trial’s own design justification. It also states that sample-size illustrations are not observed power. A planning calculation asks how much information might be needed under stated assumptions; it does not show the probability that this completed trial detected an effect, nor does it replace the observed effect estimate and its confidence interval. The numerical planning outputs are not reported in the registry record, and the record does not report the original sample-size justification.

Over-dispersion is a general issue for outcomes whose variability exceeds what a simple model assumes. In a binary endpoint, model choice and the distribution of outcomes can affect standard errors and confidence intervals. There is no reported over-dispersion assessment or model detail for this primary outcome, so none should be inferred. More broadly, statistical interpretation requires the actual estimate, uncertainty, analysis population, and assumptions; a design label or planning method alone cannot supply them.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists multiple outcomes, including several definitions of relapse and time to relapse, as well as physician global assessment, quality of life, and adverse events. It also lists 20 analyses. Considering many outcomes or analyses can raise a multiplicity question: when several statistical tests are conducted, the chance of obtaining at least one apparently notable result can increase. Researchers may address this through a prespecified hierarchy, adjustment, or careful distinction between primary and exploratory analyses. The statistical plan and any multiplicity adjustment are not reported in the registry record, so it is not possible to determine how these analyses were prioritized or interpreted.

The primary outcome definition counts early drop-outs as relapses. Other listed outcomes use different assumptions, including drop-outs treated as no relapse, drop-outs treated as having missing relapse status, and alternative rules for time-to-relapse analyses. These definitions are not interchangeable. They can produce different event classifications or use different information, and their interpretation depends on the missingness process and analysis method. Results for these analyses are not reported in the registry record.

The primary analysis population includes participants eligible after the 12-week lead-in who underwent random assignment. The record does not report whether additional populations were analyzed, how protocol deviations were handled, or how missing observations apart from the stated drop-out rules were treated. It also does not report the primary analysis model or whether adjustment for baseline characteristics was used. These details are needed to assess analysis choices and the relation between the randomized population and the analyzed population.

Alternative outcome definitions can be useful as sensitivity analyses, but their existence alone does not establish robustness. Assessment would require the results under each definition and an explanation of the assumptions. The registry record does not report a prespecified multiplicity strategy or enough analysis detail to judge the impact of missing data on the primary comparison.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: gastroenteritis (2.2%), diabetic ketoacidosis (2.2%), cholecystitis acute (2.2%), postoperative wound infection (2.2%), post procedural complication (2.2%).

The registry lists serious and other adverse-event counts separately for the open-label ustekinumab lead-in and the post-randomization groups. In the UST Open Label group, 2 participants at risk were reported with serious adverse events and 4 with other adverse events; the group at risk is 108. In the post-randomization UST, ABA/UST Placebo group, 2 of the 45 at risk were reported with serious adverse events and 6 with other adverse events. In the post-randomization UST, UST/ABA Placebo group, 5 of the 46 at risk were reported with serious adverse events and 6 with other adverse events. Deaths are reported as 0 in each group.

These are participant counts, not event counts, and the lead-in and post-randomization periods represent different treatment contexts. The record also lists serious-event terms with percentages of 2.2%, including gastroenteritis, diabetic ketoacidosis, acute cholecystitis, postoperative wound infection, post procedural complication, and back pain. The record does not give enough detail to infer comparative risk from these terms or to attribute an event to a particular treatment. Differences in reported counts should not be interpreted as causal without the study’s safety analysis, follow-up details, and appropriate uncertainty estimates, which are not reported in the registry record.

12. What the Result Does, and Does Not, Mean

The record describes a randomized comparison designed to assess psoriasis relapse after an open-label ustekinumab lead-in. Its primary endpoint is defined in detail, including a specific PASI-based threshold and a rule that counts early drop-outs as relapses. This allows the research question to be understood. It does not, by itself, show whether the randomized groups differed or how large any difference was.

The primary comparison results are not reported in the registry record. There are no arm-specific primary percentages, effect estimate, confidence interval, or test result in the record details. Therefore, the trial’s statistical evidence for or against a difference in relapse cannot be assessed. The fact that the trial is completed does not resolve that limitation. Nor does its randomized, masked design establish the direction or size of an outcome.

The outcome definition also matters to what the result would mean. The endpoint concerns relapse after the Week 12 assessment, not every aspect of psoriasis status or quality of life. Relapse is classified relative to the improvement measured at Week 12, and an early drop-out is counted as a relapse under the primary rule. Alternative assumptions are listed as secondary outcomes, but their numerical results are not reported in the registry record. The endpoint should therefore be understood as a study-specific operational definition, not as a complete description of every clinically relevant outcome.

The safety counts provide descriptive information for the recorded groups and periods. They do not establish a comparative safety profile or show that an event was caused by a treatment. The registry does not report the analysis details or uncertainty needed for a fuller comparison.

In general, a trial result is best interpreted through its estimated effect, precision, population, endpoint definition, and assumptions about missing data and multiplicity. Here, the design and definitions are available, while the primary efficacy estimates and several analysis details are not reported in the registry record. No treatment recommendation or conclusion about treatment benefit follows from the design description alone.

13. Why This Trial Matters Statistically

This trial raises a useful statistical distinction between an initial treatment response and the durability of that response. Participants first received open-label ustekinumab, and the randomized question concerns relapse after the lead-in. The primary endpoint is therefore conditional on reaching eligibility and random assignment after that period. Clear definition of this target population is important when interpreting what a randomized comparison can address.

The endpoint also illustrates how an event definition and a missing-data rule can be intertwined. Relapse is defined using PASI change from Week 12, while early drop-outs are counted as relapses in the primary outcome. That choice makes the outcome classification explicit, but also means that withdrawal behavior can affect the observed percentage. The listed alternative outcomes make clear that different assumptions about drop-outs are relevant to the interpretation. Without the numerical results under these alternatives, their influence cannot be assessed.

The trial’s randomized and masked structure is important for reducing certain sources of bias, but design labels do not replace outcome estimates and uncertainty. Statistical interpretation still depends on the observed arm results, the analysis population, the model, and the handling of missing outcomes. The registry record gives important definitions and design features but does not report the primary comparison results or enough analysis detail to evaluate those elements.

Finally, the distinction between planning and observed evidence matters. The record describes sample-size planning assumptions and identifies the calculations as illustrations, not observed power. Planning assumptions can inform design questions, but they cannot describe the precision or strength of evidence in the completed trial. That requires the observed effect and its uncertainty, which are not reported in the registry record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting efficacy is that the registry record does not report the arm-specific primary relapse percentages, the between-arm estimate, its confidence interval, or its test result. Without these, neither effect magnitude nor precision can be evaluated. The record also does not report results for the listed secondary relapse definitions, time-to-relapse outcomes, physician global assessment, or quality-of-life outcome.

The primary population is defined after the 12-week lead-in, but the record does not provide detailed eligibility criteria or participant characteristics. Enrollment is listed as 108, while post-randomization adverse-event groups are reported with risk denominators of 45 and 46. The primary efficacy denominators by arm are not reported in the registry record; group sizes should not be inferred from the enrollment figure or safety summaries.

The arm descriptions are incomplete, so post-randomization dosing and treatment schedules are not fully described. The record identifies quadruple masking but does not specify who was masked or how masking was maintained. It does not report the randomization procedure, baseline balance, analysis model, prespecified analysis plan, or multiplicity strategy. These gaps make it difficult to assess the conduct and analysis choices beyond the broad design labels.

Drop-outs are handled in several listed outcome definitions, but the number and timing of withdrawals, reasons for withdrawal, and missingness patterns are not reported in the registry record. The primary rule counts drop-outs as relapses, but its impact cannot be assessed without these details and results under alternative assumptions. The safety summaries are descriptive counts and do not include comparative uncertainty or attribution detail. These limitations restrict interpretation; they do not establish that the trial was biased or that its results would be invalid.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris — NCT01999868.
• Registry record last updated 2019-01-15; status last verified 2018-12.
• Results first posted 2018-12-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01999868 is a completed Phase 2 randomized, quadruple-masked, parallel-group study sponsored by NIAID. It lists an enrollment of 108 and concerns psoriasis. Participants received open-label ustekinumab at Weeks 0 and 4 during a 12-week lead-in, after which eligible participants underwent random assignment. The primary endpoint is the percentage experiencing psoriasis relapse from Week 12 to 88, with early drop-outs counted as relapses. The registry record defines relapse using loss of at least half of the PASI improvement measured at Week 12. It also lists secondary relapse, time-to-relapse, disease assessment, quality-of-life, and safety outcomes. The numerical primary efficacy comparison and key statistical analysis details are not reported in the registry record.